DK0946155T3 - Farmaceutiske sammensætninger til behandling af fækal inkontinens og analklöe - Google Patents

Farmaceutiske sammensætninger til behandling af fækal inkontinens og analklöe

Info

Publication number
DK0946155T3
DK0946155T3 DK97950311T DK97950311T DK0946155T3 DK 0946155 T3 DK0946155 T3 DK 0946155T3 DK 97950311 T DK97950311 T DK 97950311T DK 97950311 T DK97950311 T DK 97950311T DK 0946155 T3 DK0946155 T3 DK 0946155T3
Authority
DK
Denmark
Prior art keywords
anal
fecal incontinence
treatment
pharmaceutical compositions
patients
Prior art date
Application number
DK97950311T
Other languages
English (en)
Other versions
DK0946155T4 (da
Inventor
Michael Albert Kamm
Robin Kenneth Stewart Phillips
Original Assignee
Sla Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0946155(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9626739.8A external-priority patent/GB9626739D0/en
Priority claimed from GBGB9626750.5A external-priority patent/GB9626750D0/en
Priority claimed from GBGB9703309.6A external-priority patent/GB9703309D0/en
Application filed by Sla Pharma Ag filed Critical Sla Pharma Ag
Application granted granted Critical
Publication of DK0946155T3 publication Critical patent/DK0946155T3/da
Publication of DK0946155T4 publication Critical patent/DK0946155T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
DK97950311T 1996-12-23 1997-12-23 Farmaceutisk sammensætning til behandling af fækal inkontinens DK0946155T4 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9626739.8A GB9626739D0 (en) 1996-12-23 1996-12-23 Pharmaceutical composition for treating anal incontinence
GBGB9626750.5A GB9626750D0 (en) 1996-12-23 1996-12-23 Pharmaceutical composition for treating anal incontinence
GBGB9703309.6A GB9703309D0 (en) 1997-02-18 1997-02-18 Pharmacuetical composition for treating anal incontinence
PCT/GB1997/003525 WO1998027971A1 (en) 1996-12-23 1997-12-23 Pharmaceutical composition for treating fecal incontinence and anal itch

Publications (2)

Publication Number Publication Date
DK0946155T3 true DK0946155T3 (da) 2006-07-31
DK0946155T4 DK0946155T4 (da) 2009-05-11

Family

ID=27268647

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97950311T DK0946155T4 (da) 1996-12-23 1997-12-23 Farmaceutisk sammensætning til behandling af fækal inkontinens

Country Status (11)

Country Link
US (3) US6635678B1 (da)
EP (1) EP0946155B2 (da)
JP (1) JP4246265B2 (da)
AT (1) ATE320796T1 (da)
AU (1) AU728889C (da)
CA (1) CA2275663C (da)
DE (1) DE69735552T3 (da)
DK (1) DK0946155T4 (da)
ES (1) ES2259806T5 (da)
PT (1) PT946155E (da)
WO (1) WO1998027971A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156780A (en) * 1996-10-17 2000-12-05 Milkhaus Laboratory, Inc. Treatment of fecal incontinence
PT946155E (pt) * 1996-12-23 2006-07-31 Sla Pharma Ag Composicao farmaceutica para tratar incontinencia fecal e prurido anal
US6627632B2 (en) 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
BR9916162A (pt) * 1998-12-14 2001-09-04 Cellegy Pharma Inc Composição e método para o tratamento de um distúrbio anorretal e para controlar a dor associada com o mesmo
GB0030580D0 (en) * 2000-12-15 2001-01-31 Medicare Man Consultancy Ltd Composition and method
GB0130763D0 (en) * 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
US20040266880A1 (en) * 2002-02-22 2004-12-30 Fumie Sato Antipruritics
KR20040083416A (ko) * 2002-02-22 2004-10-01 다이쇼 세이야꾸 가부시끼가이샤 지양제
JP3678366B2 (ja) * 2002-08-09 2005-08-03 大正製薬株式会社 止痒剤
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
AU2003301900A1 (en) * 2002-11-13 2004-06-03 Fumie Sato Antipruritic drug
WO2006041875A1 (en) * 2004-10-06 2006-04-20 Allergan, Inc. Novel prostamides for the treatment of glaucoma and related diseases
AU2014202738B2 (en) * 2005-06-17 2016-05-12 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
AU2012202731B2 (en) * 2005-06-17 2014-06-19 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
AU2016202290B2 (en) * 2005-06-17 2017-10-05 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
PL1890732T3 (pl) 2005-06-17 2018-11-30 Wisconsin Alumni Research Foundation Preparaty zwężające naczynia krwionośne do podawania miejscowego i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej
WO2007130953A2 (en) 2006-05-01 2007-11-15 Duodyn Technology, Llc Apparatus and method for managing incontinence
US7828715B2 (en) * 2006-06-29 2010-11-09 Ams Research Corporation Method of treating anal incontinence
EP2120782B1 (en) * 2007-01-03 2018-10-10 Boston Scientific Scimed, Inc. Pelvic implant
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US20090156891A1 (en) * 2007-12-12 2009-06-18 Ams Research Corporation Prolapse and Perineal Repair Concepts
US8993630B2 (en) 2008-11-10 2015-03-31 Bayer Intellectual Property Gmbh Substituted sulphonamido phenoxybenzamides
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
EP2491014A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
CA2833420C (en) * 2011-04-26 2019-09-03 Rdd Pharma Ltd. Oxymetazoline for the treatment of ano-rectal disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
DK339289D0 (da) * 1989-07-07 1989-07-07 Dak Lab As Farmaceutisk praeparat
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
NL9102142A (nl) 1991-12-20 1993-07-16 Dagra Pharma Bv Zetpillen met vertraagde afgifte en werkwijze voor de bereiding daarvan.
FR2697162B1 (fr) † 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
GB9422571D0 (en) 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
US5595753A (en) * 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract
PT946155E (pt) * 1996-12-23 2006-07-31 Sla Pharma Ag Composicao farmaceutica para tratar incontinencia fecal e prurido anal

Also Published As

Publication number Publication date
CA2275663A1 (en) 1998-07-02
JP2001507020A (ja) 2001-05-29
DE69735552T3 (de) 2009-08-13
DE69735552D1 (de) 2006-05-11
ES2259806T3 (es) 2006-10-16
US20080058363A1 (en) 2008-03-06
PT946155E (pt) 2006-07-31
AU728889C (en) 2001-08-02
US6635678B1 (en) 2003-10-21
EP0946155B1 (en) 2006-03-22
WO1998027971A1 (en) 1998-07-02
DE69735552T2 (de) 2007-02-01
DK0946155T4 (da) 2009-05-11
US7781444B2 (en) 2010-08-24
US7928146B2 (en) 2011-04-19
AU728889B2 (en) 2001-01-18
US20030216420A1 (en) 2003-11-20
ES2259806T5 (es) 2009-05-01
CA2275663C (en) 2008-03-18
EP0946155A1 (en) 1999-10-06
ATE320796T1 (de) 2006-04-15
AU5331598A (en) 1998-07-17
EP0946155B2 (en) 2009-01-21
JP4246265B2 (ja) 2009-04-02

Similar Documents

Publication Publication Date Title
DK0946155T3 (da) Farmaceutiske sammensætninger til behandling af fækal inkontinens og analklöe
MY122020A (en) Use of gabab receptor agonists as reflux inhibitors
NZ520083A (en) The modification of a patient's blood with ultra-violet light for the treatment of congestive heart failure
SE9703226D0 (sv) New pharmaceutical composition
EP2329842A3 (en) Interleukin-1 inhibitors in the treatment of diseases
NO996352D0 (no) <Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
KR940005270A (ko) 뼈 손실 예방에 유용한 벤조티오펜
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
EP1889614A3 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
BR9914163A (pt) Agente para melhorar a potência excretora da bexiga urinária, uso de um composto de amina do tipo não carbamato que tenha uma ação inibidora de acetilcolinesterase, e, método para melhorar a potência excretora da bexiga urinária
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
DK1000046T3 (da) Piperazinderivater, der er aktive på den nedre urinvejskanal
WO2002046178A3 (en) Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors
WO2001022919A3 (en) Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof
DK1326592T3 (da) Anvendelse af polyethylenglycol (PEG) til fremstilling af et lægemiddel til behandling af forstoppelse
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
HRP20041150B1 (hr) Metoda za inhibiciju atrofije ili za liječenje ili prevenciju simptoma vezanih uz atrofiju kod žena
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
EA199800676A1 (ru) Способы повышения компетенции сфинктера
WO1999043308A3 (en) Treating pulmonary hypertension through tenascin suppression and elastase inhibition
DK1458376T3 (da) Darifenacin til anvendelse i behandlingen af imperiös vandladningstrang fremkaldt af overaktiv urinblære
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
WO2003006001A8 (en) ss-ADRENERGIC BLOCKADE REVERSAL OF CATABOLISM AFTER SEVERE BURN
RU2010115647A (ru) Композиция и способ лечения или профилактики доброкачественной гиперплазии предстательной железы и симптомов со стороны нижних отделов мочевыводящих путей